INTRODUCTION {#S1}
============

Tobacco addiction is a chronic disorder that is characterized by loss of control over smoking, the appearance of withdrawal symptoms upon smoking cessation, and relapse after periods of abstinence ([@R2]; [@R40]; [@R45]). Abrupt cessation of smoking typically mediates negative affective symptoms such as depressed mood, anxiety, irritability, and difficulty concentrating ([@R2]). It has been hypothesized that the negative affective aspects of tobacco withdrawal provide a powerful motivation for the continuation of smoking ([@R33]; [@R39]). Experimental evidence suggests that nicotine is one of the main components of tobacco smoke that leads to and maintains the tobacco addiction ([@R4]; [@R14]; [@R62]). The positive reinforcing effects of nicotine are at least partly mediated by the activation of neuronal nicotinic acetylcholine receptors (nAChRs). Blockade of nAChRs decreases the self-administration of nicotine in rats ([@R13]; [@R12]; [@R18]; [@R68]). In addition, mice that lack the β2-subunit of the nAChR self-administer less nicotine than wild-type controls ([@R53]). Nicotine withdrawal is associated with a deficit in brain reward function and somatic withdrawal signs in rats ([@R10]; [@R19]; [@R27]). Epping-Jordan and colleagues reported that systemic administration of the nAChR antagonist dihydro-*β*-erythroidine (DHβE) induces an elevation in brain reward thresholds (decrease in the reinforcing properties of intracranial self-stimulation) and an increase in somatic withdrawal signs in rats chronically treated with nicotine. Similarly, abrupt cessation of nicotine administration mediates an elevation in brain reward thresholds and an increase in somatic withdrawal signs ([@R19]). The administration of nicotine after the discontinuation of chronic nicotine administration has been shown to mitigate somatic nicotine withdrawal signs ([@R37]). These findings indicate that nicotine stimulates the brain reward system and discontinuation of chronic nicotine administration leads to a negative emotional state in rats.

Accumulating evidence suggests that a hyperactivity of brain stress systems may lead to a deficit in brain reward function, which is one of the core symptoms of drug withdrawal and depression ([@R5]; [@R8]). Clinical studies indicate that brain corticotropin-releasing factor (CRF) systems are hyperactive in patients with depressive disorders ([@R44]; [@R71]). Preclinical research indicates that intracerebroventricular (icv) administration of CRF induces an elevation in brain reward thresholds in rats, which is indicative of a deficit in brain reward function ([@R36]). The observation that increased CRF transmission plays a role in negative affective states has stimulated research into the role of CRF in drug addictions. These studies have provided evidence for a role of CRF in drug withdrawal-induced anxiety-like behavior. Blockade of CRF receptors has been shown to decrease anxiety-like behavior associated with withdrawal from alcohol, cocaine, and other drugs of abuse ([@R3]; [@R7]; [@R48]; [@R55]; [@R60]). Moreover, in a recent study we demonstrated that the icv administration of the non-specific CRF1/2 receptor antagonist D-Phe CRF~(12--41)~ prevents the elevations in brain reward thresholds associated with precipitated nicotine withdrawal in rats ([@R11]).

Although extensive progress has been made into the understanding of the role of CRF in drug withdrawal, it is not known via which specific brain sites CRF mediates the deficit in brain reward function associated with nicotine withdrawal. Experimental evidence points towards a role for the central nucleus of the amygdala (CeA) and the lateral bed nucleus of the stria terminalis (BNST) in the negative emotional state associated with nicotine withdrawal. Spontaneous alcohol and cocaine withdrawal and precipitated cannabinoid and nicotine withdrawal have been shown to elevate extracellular CRF levels in the CeA ([@R25]; [@R43]; [@R56]; [@R58]). In addition, alcohol withdrawal increases the release of CRF in the BNST, which can be reversed with subsequent alcohol intake ([@R47]). Another brain site that has been suggested to play an important role in drug addiction is the nucleus accumbens shell (Nacc shell). It has been suggested that the negative emotional state associated with drug withdrawal is at least partly mediated by a hypodopaminergic function in the Nacc shell ([@R6]; [@R54]). Although CRF and its receptors have been detected in the Nacc shell there is no experimental evidence suggesting a role for CRF in the Nacc shell during drug withdrawal ([@R15]; [@R64]). The administration of CRF into the lateral ventricles has been shown to induce behavioral activation in rats in a familiar environment, which is indicative of increased arousal and anxiety-like behavior, and a similar effect has been observed after the administration of CRF into the Nacc shell ([@R29]). This suggests that the release of CRF into the Nacc shell could contribute to negative emotional states.

Taken together, the above-discussed studies suggest that increased CRF transmission may play a role in the negative mood state associated with nicotine withdrawal. In addition, the CeA, BNST, and Nacc shell have been suggested to play an important role in drug withdrawal and/or relapse to drug seeking behavior ([@R32]). The aim of the present experiments was to investigate the role of CRF in the CeA, lateral BNST, and Nacc Shell in the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. The effect of the administration of the non-specific CRF1/2 receptor antagonist D-Phe CRF~(12--41)~ (CRF~1~ receptor, Ki = 56 nM; CRF~2~ receptor, Ki = 5.2 nM) into the CeA, BNST, or Nacc shell on the elevations in brain reward thresholds associated with precipitated nicotine withdrawal was investigated by using a discrete trial intracranial self-stimulation (ICSS) procedure ([@R26]; [@R52]). This procedure was used to assess the negative affective aspects of nicotine withdrawal as it provides a quantitative measure of the emotional aspects of drug withdrawal ([@R9]; [@R61]; [@R70]). In all of the experiments, response latencies were assessed to determine if the administration of the CRF receptor antagonist into the specific brain sites would affect motor output ([@R38]). Experiments that provide insight into the specific role of brain stress systems in the negative affective aspects of nicotine withdrawal may contribute to the development of non-addictive pharmacotherapies that reduce tobacco withdrawal symptomatology and improve relapse rates.

MATERIALS AND METHODS {#S2}
=====================

Subjects {#S3}
--------

Male Wistar rats (Charles River, Raleigh, NC) weighing 250--300 g at the beginning of the experiments were used. Animals were group-housed (two per cage) in a temperature- and humidity-controlled vivarium and maintained on a 12 hr light-dark cycle (lights off at 6 PM). All testing occurred at the beginning of the light cycle. Food and water were available ad libitum in the home cages. All subjects were treated in accordance with the National Institutes of Health guidelines regarding the principles of animal care. Animal facilities and experimental protocols were in accordance with the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) and approved by the University of Florida Institutional Animal Care and Use Committee.

Drugs {#S4}
-----

Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, and pentobarbital sodium salt were purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA) and dissolved in sterile saline (0.9% sodium chloride). The CRF1/2 receptor antagonist \[DPhe12, Nle21, 38CαMe Leu37\]r/hCRF(12--41) (D-Phe CRF~(12--41)~) was synthesized by The Clayton Foundation Laboratories for Peptide Biology and kindly provided by Dr. Jean Rivier (Salk Institute for Biological Studies, La Jolla, CA). D-Phe CRF~(12--41)~ was dissolved in distilled water and kept on ice until being used in the behavioral experiments. The CRF receptor antagonist was administered within one hour after being dissolved.

Surgical Procedures {#S5}
-------------------

### Cannulae and electrode implantations {#S6}

At the beginning of all the intracranial surgeries, the rats were anesthetized with an isoflurane/oxygen vapor mixture (1--3% isoflurane) and placed in a Kopf stereotaxic frame (David Kopf Instruments, Tujunga, CA) with the incisor bar set 3.3 mm below the interaural line (flat skull). The rats were prepared with 11 mm stainless steel 23 gauge cannulae above the CeA, lateral BNST, or Nacc Shell using flat skull coordinates according to [@R50], and a previous study by Koob and colleagues ([@R23]). Bilateral cannulae were implanted 2.5 mm above the CeA (anterior-posterior \[AP\] −2.3, medial lateral \[ML\] ±4.0 mm, dorsal-ventral \[DV\] −4.7 from dura), 2.0 mm above the lateral BNST (AP −0.6, ML ±3.7 and 15° vertical tilt, DV −4.6 from dura), or 2.5 mm above the Nacc shell (AP +1.7 mm, ML ±1.0, DV −5.1 from dura). At the end of the surgery, 11 mm removable 30 gauge wire stylets were inserted in the cannulae to maintain patency. For the electrode implantations, the incisor bar was set 5 mm (CeA and BNST groups) above the interaural line or at the interaural line (Nacc shell group). The position of the incisor bar had to be adjusted for the electrode implantations in the Nacc shell group in order to be able to accommodate the cannulae and the electrode. The rats were prepared with stainless steel bipolar electrodes (model MS303/2 Plastics One, Roanoke, VA) 11 mm in length in the medial forebrain bundle at the level of the posterior lateral hypothalamus (AP −0.5 mm, ML ±1.7 mm, DV −8.3 mm from dura). The electrodes and cannulae were permanently secured to the skull using dental cement anchored with four skull screws.

### Osmotic minipump implantations {#S7}

The rats were prepared with osmotic minipumps (model 2ML4, 28 day pumps, Durect Corporation, Cupertino, CA) filled with either saline or nicotine hydrogen tartrate dissolved in saline. The pumps were implanted subcutaneously under isoflurane/oxygen (1--3% isoflurane) anesthesia. The nicotine concentration was adjusted to compensate for differences in body weight and to deliver a dose of 9 mg/kg/day of nicotine salt (3.16 mg/kg/day nicotine base).

Apparatus {#S8}
---------

The experimental apparatus consisted of twelve Plexiglas chambers (30.5 × 30 × 17 cm; Med Associates, Georgia, VT), each housed in a sound-attenuating melamine chamber (Med Associates, Georgia, VT). The operant conditioning chambers consisted of a metal grid floor and a metal wheel (5 cm wide) centered on a sidewall. A photobeam detector was attached next to the response wheel and recorded every 90 degrees of rotation. Brain stimulation was delivered by constant current stimulators (Model 1200C, Stimtek, Acton, MA). Subjects were connected to the stimulation circuit through bipolar leads (Plastics One, Roanoke, VA) attached to gold-contact swivel commutators (model SL2C Plastics One, Roanoke, VA). A computer controlled the stimulation parameters, data collection, and all test session functions.

Intracranial self-stimulation procedure {#S9}
---------------------------------------

Rats were trained on a modified discrete-trial ICSS procedure ([@R35]), as described previously ([@R38]). The subjects were trained initially to turn the wheel on a fixed ratio 1 (FR1) schedule of reinforcement. Each quarter turn resulted in the delivery of a 0.5 second train of 0.1 millisecond cathodal square-wave pulses at a frequency of 100 Hz. After the successful acquisition of responding, defined as 100 reinforcements within 10 minutes, the rats were gradually trained on a discrete-trial current-threshold procedure. Each trial began with the delivery of a non-contingent electrical stimulus, followed by a 7.5 second response window within which the animal could respond to receive a second contingent stimulus identical to the initial non-contingent stimulus. A response during this 7.5 second response window was labeled as a positive response and the lack of a response was labeled as a negative response. During a 2-second period immediately after a positive response, additional responses had no scheduled consequences. The inter-trial interval (ITI), which followed either a positive response or the end of the response window, had an average duration of 10 seconds (7.5 -- 12.5 seconds). Responses that occurred during the ITI resulted in a further 12.5 second delay of the onset of the next trial. During training on the discrete-trial procedure, the duration of the ITI and delay periods induced by time-out responses were gradually increased until animals performed consistently at standard test parameters. The rats were subsequently tested on the current-threshold procedure in which stimulation intensities varied according to the classical psychophysical method of limits. A test session consisted of four alternating series of descending and ascending current intensities starting with a descending series. Blocks of three trials were presented to the subject at a given stimulation intensity, and the intensity was altered systematically between blocks by 5 μA steps. The initial stimulus intensity was set 40 μA above the baseline current-threshold for each animal. Each test session typically lasted 30--40 minutes and provided two variables: brain reward thresholds and response latencies. The brain reward threshold for a descending series was defined as the midpoint between stimulation intensities that supported responding (i.e., positive responses on at least two of the three trials), and current intensities that failed to support responding (i.e., positive responses on fewer than two of the three trials for two consecutive blocks of trials). The threshold for an ascending series was defined as the midpoint between stimulation intensities that did not support responding and current intensities that supported responding for two consecutive blocks of trials. Four threshold estimates were recorded and the mean of these values was taken as the brain reward threshold for a specific subject. The response latency was defined as the time interval between the beginning of the non-contingent stimulus and a positive response. The response latency for each test session was defined as the mean response latency on all trials during which a positive response occurred.

Intracerebral microinjections {#S10}
-----------------------------

The bilateral injections were administered by using 30 gauge stainless steel injectors that extended 2.5 mm (length of injector tip, 13.5 mm; CeA and Nacc Shell) or 2.0 mm (length of injector tip, 13.0 mm; BNST) beyond the guide cannulae. The injection volume was 0.5 μl/side and this was infused over 66 seconds. The infusion speed was regulated by a Harvard Apparatus syringe pump (model 975) and the pump was equipped with 10 μl syringes (Hamilton, Rena, NE). The syringes were connected to the injectors with Tygon microbore PVC tubing (0.25 mm ID × 0.76 mm OD). The injectors were left in place for 30 seconds post-injection to allow diffusion from the injector tip. The dummy stylets, 11 mm, were re-inserted immediately after the injectors were removed.

Histology {#S11}
---------

At the end of the experiments, the rats were euthanized with an overdose of sodium pentobarbital (150 mg, intraperitoneally) and perfused via the ascending aorta with physiological saline (100 ml) followed by a 10% phosphate buffered formalin solution (150 ml). Brains were postfixed for 24 hours and cryoprotected in 10% sucrose in phosphate buffered saline for 48 hours. Sections were cut on a Leica CM3050 S cryostat (coronal sections of 40 μm at −15 °C). The sections were mounted on Fisher Superfrost Plus slides and stained with cresyl violet. The locations of the guide cannulae and injections sites were verified with light microscopy and with reference to a stereotaxic atlas of the rat brain ([@R50]).

Experimental Design {#S12}
-------------------

### Effect of D-Phe CRF~(12--41)~ administered into the CeA, BNST or Nacc shell on precipitated nicotine withdrawal {#S13}

Naïve rats were used for all the experiments. After recovery from the electrode implantations, the rats were trained on the ICSS procedure. When stable baseline brain reward thresholds were achieved (defined as less than 10% variation within a 5 day period), the rats were prepared with 28-day osmotic minipumps containing either saline or nicotine dissolved in saline (CeA: saline n=8, nicotine n=8; BNST: saline n=9, nicotine n=9; Nacc shell: saline n=9, nicotine n=9). Brain reward thresholds and response latencies were assessed daily throughout the experiment between 9:00 AM and 12:00 noon. The nAChR antagonist mecamylamine (3 mg/kg, sc) was used to precipitate nicotine withdrawal. Mecamylamine injections started at least 6 days after the implantation of the minipumps to allow time for the development of nicotine dependence. The CRF1/2 receptor antagonist D-Phe CRF~(12--41)~ (5 -- 500 ng per brain site) was administered 10 minutes prior to treatment with mecamylamine. The rats were placed in the ICSS test chambers 5 minutes after mecamylamine administration. It was ensured that the minimum time interval between the mecamylamine injections was at least 72 hours to reestablish/maintain nicotine dependence. The serum elimination half-life of mecamylamine is approximately 1 hour ([@R16]). At the end of the experiment the rats were perfused under pentobarbital anesthesia and the brains were removed for histological verification of the cannulae placements.

Statistical analyses {#S14}
--------------------

For all the experiments, brain reward thresholds and response latencies were expressed as percentages of the values obtained on the day prior to each test day. Percent changes in brain reward thresholds and response latencies were analyzed using a two-way repeated-measures analyses of variance (ANOVA) with the dose of D-Phe CRF~(12--41)~ as the within-subjects factor and pump content (saline or nicotine) as the between-subjects factor. For all experiments, statistically significant interactions in the ANOVA were followed by the Newman-Keuls post-hoc test.

RESULTS {#S15}
=======

Effect of D-Phe CRF~(12--41)~ administered into the CeA on precipitated nicotine withdrawal {#S16}
-------------------------------------------------------------------------------------------

Mean (±S.E.M.) absolute brain reward thresholds before pump implantation for saline- and nicotine-treated rats were 87.14 ± 3.39 and 88.23 ± 6.66 μA \[t(14)=0.15, n.s.\], respectively. Mean (±S.E.M.) absolute response latencies for saline- and nicotine-treated rats were 2.90 ± 0.10 and 3.08 ± 0.15 seconds \[t(14)=1.00, n.s.\], respectively. Mecamylamine elevated the brain reward thresholds of the nicotine-treated rats, 146%, and did not affect the brain reward thresholds of the control rats ([Figure 1A](#F1){ref-type="fig"}, Treatment: F1, 14=57.46, P\<0.0001). Mecamylamine did not affect the response latencies of the nicotine-treated rats or the saline-treated rats ([Figure 1B](#F1){ref-type="fig"}, Treatment: F1, 14=3.49, n.s.). The administration of D-Phe CRF~(12--41)~ into the CeA prevented the mecamylamine-induced elevations in brain reward thresholds in the nicotine dependent rats and did not affect the brain reward thresholds of the rats that were chronically-treated with saline ([Figure 1A](#F1){ref-type="fig"}; Dose × Treatment interaction: F3, 42=4.21, P\<0.011). Newman-Keuls post-hoc comparisons indicated that 500 ng of D-Phe CRF~(12--41)~ per brain site completely prevented the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. D-Phe CRF~(12--41)~ did not affect the response latencies ([Figure 1B](#F1){ref-type="fig"}; Dose: F3, 42=1.23, n.s.; Dose × Treatment interaction: F3, 42=0.17, n.s.). See [figure 4A](#F4){ref-type="fig"} for a histological reconstruction of the injections sites.

Effect of D-Phe CRF~(12--41)~ administered into the BNST on precipitated nicotine withdrawal {#S17}
--------------------------------------------------------------------------------------------

Mean (±S.E.M.) absolute brain reward thresholds before minipump-implantation for the saline-treated rats and the nicotine-treated rats were 118.84 ± 8.78 and 118.93 ± 14.17 μA \[t(16)=0.01, n.s.\], respectively. Mean (±S.E.M.) absolute response latencies for the saline-treated rats and the nicotine-treated rats were 3.28 ± 0.16 and 2.99 ± 0.10 seconds \[t(16)=1.61, n.s.\], respectively. Similar to the first experiment, mecamylamine elevated the brain reward thresholds of the nicotine treated rats, 147%, and did not affect the brain reward thresholds of the saline-treated rats ([Figure 2A](#F2){ref-type="fig"}, Treatment: F1, 16=17.33, P\<0.0007). Mecamylamine did not affect the response latencies of the nicotine-treated rats or the saline-treated rats ([Figure 2B](#F2){ref-type="fig"}, Treatment: F1, 16=3.21, n.s.). The administration of D-Phe CRF~(12--41)~ into the BNST did not affect the brain reward thresholds (Dose: F3, 48=0.64, n.s.; Dose × Treatment: F3, 48=0.61, n.s.) or the response latencies (Dose: F3, 48=0.92, n.s.; Dose × Treatment: F3, 48=2.40, n.s.) of the saline-treated rats or the nicotine-treated rats. See [figure 4B](#F4){ref-type="fig"} for a histological reconstruction of the injections sites.

Effect of D-Phe CRF~(12--41)~ administered into the Nacc Shell on precipitated nicotine withdrawal {#S18}
--------------------------------------------------------------------------------------------------

Mean (±S.E.M.) absolute brain reward thresholds before minipump-implantation for the saline-treated rats and the nicotine-treated rats were 139.21 ± 14.54 and 136.99 ± 15.18 μA \[t(16)=0.11, n.s.\], respectively. Mean (±S.E.M.) absolute response latencies for the saline-treated rats and the nicotine-treated rats were 3.61 ± 0.17 and 3.93 ± 0.17 seconds \[t(16)=1.33, n.s.\], respectively. Mecamylamine elevated the brain reward thresholds of the nicotine treated rats, 151%, and did not affect the brain reward thresholds of the saline-treated rats ([Figure 3A](#F3){ref-type="fig"}, Treatment: F1, 16=59.44, P\<0.0001). Mecamylamine did not affect the response latencies of the nicotine-treated rats or the saline-treated rats ([Figure 3B](#F3){ref-type="fig"}, Treatment: F1, 16=0.77, n.s.). The administration of D-Phe CRF~(12--41)~ into the Nacc shell prevented the mecamylamine-induced elevations in brain reward thresholds in the nicotine dependent rats and did not affect the brain reward thresholds of the rats that were chronically-treated with saline ([Figure 3A](#F3){ref-type="fig"}; Dose × Treatment interaction: F3, 48=3.48, P\<0.023). Post-hoc analysis indicated that the highest dose of D-Phe CRF~(12--41)~, 500 ng per site, completely prevented the mecamylamine-induced elevations in brain reward thresholds in the nicotine-treated rats. The administration of D-Phe CRF~(12--41)~ into the Nacc Shell did not affect the response latencies of the saline-treated rats or the nicotine-treated rats (Dose: F3, 48=0.35, n.s.; Dose × Treatment: F3, 48=1.07, n.s.). See [figure 4C](#F4){ref-type="fig"} for a histological reconstruction of the injections sites.

DISCUSSION {#S19}
==========

These results demonstrate that the nAChR antagonist mecamylamine elevates the brain reward thresholds of rats that are chronically treated with nicotine and does not affect the brain reward thresholds of saline-treated control rats, which is in line with previous studies ([@R10]; [@R19]; [@R69]). The administration of D-Phe CRF~(12--41)~ (500 ng/site) into the CeA and the Nacc shell prevented the mecamylamine-induced elevations in brain reward thresholds. In contrast, the administration of D-Phe CRF~(12--41)~ into the lateral BNST did not prevent the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. Our findings extend and corroborate previous findings by demonstrating that antagonism of CRF1/2 receptors in the CeA and Nacc shell, but not in the lateral BNST, prevents the negative affective state of precipitated nicotine withdrawal in rats ([@R11]; [@R19]).

These studies focused on investigating the role of CRF in the CeA, lateral BNST, and Nacc shell in nicotine withdrawal as all of these structures are considered part of the extended amygdala, are highly interconnected, and have overlapping afferent and efferent connections ([@R1]; [@R28]). In addition, it has been suggested that the extended amygdala plays a critical role in the negative affective state associated with drug withdrawal ([@R34]). Extensive evidence points toward a role for CRF in the CeA in drug addictions. Withdrawal from alcohol ([@R43]), cannabis ([@R58]), cocaine ([@R56]), and nicotine ([@R25]) has been shown to induce an increased release of CRF in the CeA. It has also been shown that alcohol withdrawal-induced anxiety-like behavior in the elevated plus maze test can be reversed by the administration of the nonspecific CRF1/2 receptor antagonist α-helical CRF~(9--41)~ in the lateral ventricles ([@R3]) or the CeA ([@R55]). Koob and colleagues demonstrated that alcohol intake in rats is increased after chronic exposure to alcohol vapor ([@R57]) and the increased alcohol intake in the alcohol dependent animals can be prevented by the administration of D-Phe CRF~(12--41)~ into the CeA prior to the alcohol self-administration sessions ([@R23]). The results of our study demonstrated that antagonism of CRF receptors in the CeA prevented the elevations in brain reward thresholds associated with nicotine withdrawal. This suggests that the release of CRF into the CeA may at least partly mediate the deficit in brain reward function associated with nicotine withdrawal. Drug intake during the withdrawal phase could possibly diminish negative affective states by decreasing the release of CRF in the CeA.

The intra-CeA dose of D-Phe CRF~(12--41)~ that prevented the elevations in brain reward thresholds was about 20 times lower than the icv dose required to prevent the elevations in brain reward thresholds associated with nicotine withdrawal (1 μg intra-CeA \[total bilateral dose\] vs. 20 μg icv)([@R11]). This suggests that the current total bilateral dose, 1 μg of D-Phe CRF~(12--41)~, would not have prevented the deficit in brain reward function associated with nicotine withdrawal when administered into the lateral ventricles. This rules out the possibility that in the present studies D-Phe CRF~(12--41)~ diffused into the lateral ventricles and then mediated its effects by acting upon other brain sites. It is also unlikely that D-Phe CRF~(12--41)~ prevented the elevations in brain reward thresholds by activating brain reward systems. The icv administration of D-Phe CRF~(12--41)~ does not alter brain reward thresholds in drug free rats ([@R36]). In addition, in the present study we showed that intra-CeA, BNST, or Nacc shell administration of D-Phe CRF~(12--41)~ does not affect the brain reward thresholds of the chronic saline/acute mecamylamine control group.

Some studies suggest that the BNST may be involved in specific aspects of drug addictions. Discontinuation of chronic alcohol administration increases extracellular CRF levels in the BNST, which subsides with subsequent alcohol intake ([@R47]). In addition, naloxone induces a dose-dependent increase in c-fos mRNA in the BNST of morphine dependent animals ([@R21]). Evidence for a role of the BNST in negative affective states is provided by Aston-Jones and colleagues ([@R17]). They reported that the blockade of β-noradrenergic receptors or activation of α2-adrenergic receptors in the BNST prevents opioid withdrawal-induced conditioned place aversion. At this point in time, we are not aware of any studies which reported that blockade of CRF receptors in the BNST prevents the negative affective state associated with drug withdrawal. The results of our study suggest that the activation of CRF receptors in the BNST does not play a role in the negative emotional state associated with nicotine withdrawal. This is in agreement with a previous study showing that blockade of CRF receptors in the BNST does not reduce alcohol intake in alcohol dependent rats ([@R23]). It is unlikely that the doses of D-Phe CRF~(12--41)~ were too low in the present study as the same doses prevented the negative emotional state associated with nicotine withdrawal when administered into the CeA or Nacc shell. In addition, a previous study reported that the intra-BNST administration of doses of D-Phe CRF~(12--41)~, that are within the current dose-response range (10 or 50 ng/side administered bilaterally), prevent stress-induced reinstatement of cocaine seeking behavior ([@R20]).

Emerging evidence suggests that CRF in the CeA and BNST may have a distinct role in various aspects of drug addictions and anxiety and fear responses ([@R20]; [@R67]). The present studies suggest that CRF in the CeA, but not in the BNST, plays a role in the negative affective state associated with nicotine withdrawal. CRF in the CeA, but not in the BNST, has also been suggested to play a role in the increased alcohol intake in alcohol dependent animals ([@R23]). Furthermore, the administration of the CRF1/2 receptor antagonist alpha-helical CRF~(9--41)~ into the CeA, but not into the BNST, reduced the severity of naloxone-precipitated somatic morphine withdrawal signs ([@R41]). The aforementioned studies suggest that CRF signaling in the CeA mediates acute drug withdrawal signs such as elevations in brain reward thresholds, somatic signs, and increased drug intake. In contrast, CRF transmission in the BNST may at least partly mediate protracted drug withdrawal signs such as stress-induced reinstatement of drug seeking behavior. For example, Erb and Stewart demonstrated that the BNST, but not the CeA, plays a role in stress-induced reinstatement of cocaine seeking behavior ([@R20]).

Neurochemical changes in the Nacc shell have been implicated in the negative affective state associated with drugs withdrawal. For example, nicotine withdrawal has been associated with a decrease in dopamine levels and an increase in acetylcholine levels in the Nacc shell in rats ([@R54]). The Nacc shell contains CRF-immunoreactive cells and moderate levels of CRF1 and CRF2 receptors have been detected in this brain site ([@R15]; [@R42]; [@R59]; [@R64]). However, very little research has been conducted to investigate the role of CRF in the Nacc shell in drug addiction. The results of the present study indicate that the administration of the CRF1/2 receptor antagonist D-Phe CRF~(12--41)~ into the Nacc shell prevents the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. Thus, this suggests that the negative affective state associated with nicotine withdrawal is at least partly mediated by the release of CRF in the Nacc shell. Research by Koob and colleagues suggests that CRF in the Nacc shell does not play a role in alcohol intake in alcohol dependent rats ([@R23]). However, emerging evidence suggests that CRF in the Nacc shell has behavioral effects and could play a role in psychiatric disorders. The icv administration of CRF has been shown to increase locomotor activity in rats in a familiar environment and to increase anxiety-like behavior in a novel environment ([@R63]; [@R65]). Kelley and colleagues demonstrated that the administration of CRF into the Nacc shell also increases locomotor activity in rats in a familiar environment ([@R29]), which suggests that CRF might mediate some of its behavioral effects by stimulating CRF receptors in the Nacc shell. In a recent study it was demonstrated that the administration of CRF into the Nacc shell increases cue-induced motivation to obtain sucrose pellets ([@R51]). It was suggested that the CRF release in the Nacc shell may also increase the motivation to obtain other positive reinforcers such as drugs of abuse and therefore play a role in the reinstatement of drug seeking behavior.

D-Phe CRF~(12--41)~ is a nonspecific CRF receptor antagonist and therefore the present studies did no distinguish between CRF1 and CRF2 receptor subtypes. Extensive evidence suggests that the CRF1 receptor plays a pivotal role in drug withdrawal and relapse. Systemic administration of the small-molecule non-peptide CRF1 receptor antagonist MPZP has been shown to decrease nicotine withdrawal-induced anxiety-like behavior and to prevent increased nicotine intake after a period of abstinence ([@R25]). Furthermore, the non-peptide CRF1 receptor antagonist MTIP blocks alcohol withdrawal induced anxiety-like behavior, excessive alcohol self-administration in alcohol dependent rats, and stress-induced reinstatement of alcohol seeking behavior ([@R24]). Conflicting findings have been reported with regard to the role of the CRF2 receptor in drug withdrawal. Stimulation of CRF2 receptors decreases alcohol intake in alcohol dependent animals and decreases alcohol withdrawal-induced anxiety-like behavior ([@R22]; [@R66]). In contrast, CRF2 receptor knockout mice display decreased somatic morphine withdrawal signs, which suggests that activation of CRF2 receptors contributes to drug withdrawal ([@R49]). The above discussed studies would suggest that the activation of the CRF1 receptor may play an important role in the negative affective state of nicotine withdrawal. At this point in time, additional studies are needed before firm conclusions can be drawn about the role of the CRF2 receptor in drug withdrawal.

In the present studies, the role of CRF in nicotine withdrawal was investigated in rats passively exposed to nicotine. It should be noted that passive exposure to nicotine and nicotine self-administration may have different effects on brain chemistry and brain reward function ([@R19]; [@R30]; [@R31]). Therefore, additional studies are warranted to investigate the role of CRF in changes in brain reward function after discontinuing chronic nicotine self-administration. Previous research has shown that extended access to nicotine self-administration, 23 hours per day, leads to nicotine dependence as indicated by precipitated somatic withdrawal signs ([@R46]). Somatic withdrawal signs were not recorded in the present study. However, future studies may investigate the effect of the administration of CRF receptor antagonists in specific brain sites on affective and somatic withdrawal signs as this may help to delineate the neuronal substrates underlying the negative affective and somatic withdrawal signs.

Taken together, the present findings indicate that blockade of CRF1/2 receptors in the CeA and Nac Shell, but not in the lateral BNST, prevents the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. These studies point toward an important role for CRF in the CeA and Nacc shell in the negative affective state associated with smoking cessation. Further studies are warranted to investigate the role of specific CRF receptor subtypes in the extended amygdala in the negative affective state associated with smoking cessation.
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###### 

Effect of D-Phe CRF~(12--41)~ (saline, n = 8; nicotine, n = 8) administered into the CeA on the elevations in brain reward thresholds associated with mecamylamine-precipitated nicotine withdrawal (A). Effect of D-Phe CRF~(12--41)~ on the response latencies of rats chronically treated with saline (n = 8) or nicotine (n = 8) and acutely treated with mecamylamine (B). Brain reward thresholds and response latencies are expressed as a percentage of the pre-test day values. D-Phe CRF~(12--41)~ was administered bilaterally and the figure depicts the unilateral dose. Asterisks (\*\* P\<0.01) indicate elevations in brain reward thresholds compared to those of the corresponding saline-treated control group. Pound signs (\#\# P\<0.01) indicate lower brain reward thresholds compared to those of rats chronically treated with nicotine and acutely treated with mecamylamine and vehicle (0 μg of D-Phe CRF~(12--41)~). Abbreviation: ic, intracranial.
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###### 

Effect of D-Phe CRF~(12--41)~ (saline, n = 9; nicotine, n = 9) administered into the BNST on the elevations in brain reward thresholds associated with mecamylamine-precipitated nicotine withdrawal (A). Effect of D-Phe CRF~(12--41)~ on the response latencies of rats chronically treated with saline (n = 8) or nicotine (n = 8) and acutely treated with mecamylamine (B). Brain reward thresholds and response latencies are expressed as a percentage of the pre-test day values. D-Phe CRF~(12--41)~ was administered bilaterally and the figure depicts the unilateral dose. Abbreviation: ic, intracranial.
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###### 

Effect of D-Phe CRF~(12--41)~ (saline, n = 9; nicotine, n = 9) administered into the Nacc shell on the elevations in brain reward thresholds associated with mecamylamine-precipitated nicotine withdrawal (A). Effect of D-Phe CRF~(12--41)~ on the response latencies of rats chronically treated with saline (n = 9) or nicotine (n = 9) and acutely treated with mecamylamine (B). Brain reward thresholds and response latencies are expressed as a percentage of the pre-test day values. D-Phe CRF~(12--41)~ was administered bilaterally and the figure depicts the unilateral dose. Asterisks (\*\* P\<0.01) indicate elevations in brain reward thresholds compared to those of the corresponding saline-treated control group. Pound signs (\#\# P\<0.01) indicate lower brain reward thresholds compared to those of rats chronically treated with nicotine and acutely treated with mecamylamine and vehicle (0 μg of D-Phe CRF~(12--41)~). Abbreviation: ic, intracranial.
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Histological reconstruction of bilateral injection sites in the CeA (A) of rats chronically treated with nicotine (+, n = 8) or saline (\*, n = 8). Reconstruction of bilateral injection sites in the lateral BNST (B) of rats chronically treated with nicotine (+, n = 9) or saline (\*, n = 9). Reconstruction of bilateral injections sites in the Nacc shell (C) of rats chronically treated with nicotine (+, n = 9) or saline (\*, n = 9). The figures are copies from the Paxinos and Watson brain atlas ([@R50]).
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